Fifth Third Wealth Advisors LLC Has $1.93 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

Fifth Third Wealth Advisors LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 36.3% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 6,185 shares of the medical research company's stock after buying an additional 1,647 shares during the period. Fifth Third Wealth Advisors LLC's holdings in Amgen were worth $1,927,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in AMGN. Centricity Wealth Management LLC bought a new stake in Amgen in the fourth quarter valued at about $25,000. Pinney & Scofield Inc. bought a new stake in Amgen in the fourth quarter valued at about $26,000. Ritter Daniher Financial Advisory LLC DE increased its stake in Amgen by 66.2% in the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares during the period. Synergy Investment Management LLC bought a new stake in Amgen in the fourth quarter valued at about $34,000. Finally, Atala Financial Inc bought a new stake in Amgen in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on AMGN. Wells Fargo & Company reissued an "equal weight" rating on shares of Amgen in a research note on Wednesday, February 5th. Cantor Fitzgerald began coverage on shares of Amgen in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $305.00 price objective on the stock. Morgan Stanley reaffirmed an "equal weight" rating on shares of Amgen in a research note on Friday, May 2nd. Guggenheim began coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective on the stock. Finally, Erste Group Bank cut shares of Amgen from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 8th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Trading Up 0.0%

NASDAQ AMGN traded up $0.09 during trading hours on Thursday, hitting $287.10. The company's stock had a trading volume of 2,521,343 shares, compared to its average volume of 2,809,729. The stock has a fifty day moving average of $281.91 and a 200 day moving average of $285.36. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The firm has a market capitalization of $154.38 billion, a P/E ratio of 38.03, a PEG ratio of 2.63 and a beta of 0.51. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The business had revenue of $8.15 billion for the quarter, compared to analyst estimates of $8.05 billion. During the same period in the prior year, the business posted $3.96 earnings per share. Amgen's revenue was up 9.4% compared to the same quarter last year. Equities research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.